Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity
NCT ID: NCT00178230
Last Updated: 2017-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
82 participants
OBSERVATIONAL
1996-03-15
2013-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of Circulating Biomarkers of Immunogenic Cell Death
NCT02921854
Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal Injury
NCT00631839
A Study For Using Radiosurgery On Limited Metastases
NCT00178399
Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer
NCT03706027
Risk Factors of Radiation Pneumonitis
NCT00155909
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients receiving HDR Brachytherapy for lung cancer.
Patients receiving concomitant radiation and interferon therapy for lung cancer.
Patients receiving concomitant chemotherapy and radiation for lung cancer. Prior drug therapy does not make patients ineligible.
Karnofsky ≥ 70 %.
There are no age restrictions.
Acceptable bone marrow function - WBC 2 3000/mm3, platelet count \> 100,000, hematocrit ≥ 33%, hemoglobin ≥ 11 gms/dl.
Life expectancy \> 6 months.
Patients must sign informed consent meeting all federal and institutional guidelines.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Rochester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuhchyau Chen
Proffessor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuhchyau Chen, MD, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Universtiy of Rochester, Dept of Radiation Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rochester, Dept. Radiation Oncology
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
URCC 4595
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.